The Clinical Pharmacology Training Program at Johns Hopkins is designed to train highly-qualified physicians and pharmacists to become independent clinical investigators applying the tools of clinical pharmacology to advance drugs from the laboratory to the clinical treatment and prevention of disease in people. This program addresses a critical shortage of well-trained clinician-scientists who conduct hands-on studies in humans, particularly in the area of clinical pharmacology. The program is centered in the Division of Clinical Pharmacology, which is jointly within the Department of Medicine and the Department of Pharmacology and Molecular Sciences, in the School of Medicine. This venue is ideal for conducting research that translates basic molecular discoveries into clinical trials. The training program takes about four years to complete and includes a core curriculum in clinical pharmacology (coursework, conferences, experiential rotations, and research) as well as matriculation in the PhD track of the Graduate Training Program in Clinical Investigation in the School of Public Health. In keeping with the collective expertise of the Division faculty, research commonly focuses on anti-infective drugs, and has been expanded to include oncology, pediatrics, pharmacoepidemiology, and obstetrics and gynecology, among other areas. Each trainee has a mentoring team who oversees the fellow's progress in the principles and analytical disciplines of clinical pharmacology, thesis research, and professional development. Participating faculty are carefully chosen and committed to playing a critical mentoring role for the fellows. Although there are no clinical care responsibilities in the program apart from clinical research, fellows may complete a concurrent clinical subspecialty fellowship. The program solicits and receives the regular advice of an Advisory Board comprised of distinguished translational- or clinician-scientists and outstanding clinical pharmacology educators from within and outside of Johns Hopkins. After completion of this rigorous, comprehensive, and nurturing program, most graduates have achieved board eligibility in Clinical Pharmacology, board eligibility in a medical sub-specialty clinical area (MDs), and a PhD in Clinical Investigation. Graduates have the skills and knowledge to step directly into an independent research careers, nearly all as Assistant Professors, at the interface of basic and clinical pharmacology.
This program trains physicians and pharmacists in the principles and practice of Clinical Pharmacology, a branch of science that focuses on the study of drugs in humans and that brings basic lab discoveries into clinical practice. In a three to four year program, trainees will have rigorous in-class education and will conduct clinical studies of drugs in humans.
|Coleman, Jenell S; Fuchs, Edward; Aung, Wutyi S et al. (2016) Feasibility of radiolabeled small molecule permeability as a quantitative measure of microbicide candidate toxicity. Contraception 93:331-336|
|Jackson, Sadhana; Anders, Nicole M; Mangraviti, Antonella et al. (2016) The effect of regadenoson-induced transient disruption of the blood-brain barrier on temozolomide delivery to normal rat brain. J Neurooncol 126:433-9|
|Phillips, Patrick P J; Dooley, Kelly E; Gillespie, Stephen H et al. (2016) A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP). BMC Med 14:51|
|Hendrix, Craig W; Andrade, Adriana; Bumpus, Namandjé N et al. (2016) Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). AIDS Res Hum Retroviruses 32:32-43|
|Conde, Marcus B; Mello, Fernanda C Q; Duarte, Rafael Silva et al. (2016) A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis. PLoS One 11:e0154778|
|Gupta, Amita; Mathad, Jyoti S; Abdel-Rahman, Susan M et al. (2016) Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. Clin Infect Dis 62:761-769|
|Svensson, Elin M; Acharya, Chayan; Clauson, Björn et al. (2016) Pharmacokinetic Interactions for Drugs with a Long Half-Life—Evidence for the Need of Model-Based Analysis. AAPS J 18:171-9|
|Hoffmann, Christopher J; Cohn, Silvia; Mashabela, Fildah et al. (2016) Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa. J Acquir Immune Defic Syndr 71:31-7|
|Dooley, Kelly E; Phillips, Patrick P J; Nahid, Payam et al. (2016) Challenges in the clinical assessment of novel tuberculosis drugs. Adv Drug Deliv Rev 102:116-22|
|Hiruy, Hiwot; Fuchs, Edward J; Marzinke, Mark A et al. (2015) A Phase 1 Randomized, Blinded Comparison of the Pharmacokinetics and Colonic Distribution of Three Candidate Rectal Microbicide Formulations of Tenofovir 1% Gel with Simulated Unprotected Sex (CHARM-02). AIDS Res Hum Retroviruses 31:1098-108|
Showing the most recent 10 out of 41 publications